The transaction follows a 2022 strategic partnership and co-promotion agreement between the two companies. Medtronic confirmed that it has exercised its option to purchase the remaining shares of CathWorks for a total consideration of up to $585 million, plus potential undisclosed earn-out payments. The deal underscores a broader industry shift toward non-invasive, data-heavy diagnostic tools in cardiovascular medicine.
In section Market Quotes
Medtronic to Buy CathWorks for $585M to Boost AI Cardiac Diagnostics
Medtronic announced Tuesday it has exercised an option to acquire medical technology firm CathWorks for up to $585 million, a move aimed at integrating AI-driven diagnostics into the treatment of coronary artery disease.
At the heart of the acquisition is the CathWorks FFRangio System, an artificial-intelligence-powered platform designed to assess coronary artery disease. Unlike traditional Fractional Flow Reserve (FFR) treatments that require invasive pressure wires and drug-induced stress, the CathWorks system uses routine angiograms to provide real-time data. Jason Weidman, head of Medtronic’s coronary and renal denervation business, stated that the technology allows the company to "transform the cath lab" by driving individualized treatment standards.
Comments (0)
No comments yet. Be the first!